Growth hormone–releasing hormone (GHRH) is a hypothalamic peptide that plays an essential role in the regulation of growth hormone (GH) secretion from the anterior pituitary gland. It acts as a central component of the neuroendocrine axis that modulates growth, metabolism, and many peripheral functions. GHRH binds to specific G protein–coupled receptors (GHRH-R) on pituitary somatotrophs to stimulate the synthesis and release of GH, which in turn mediates growth-promoting effects either directly or indirectly through the production of insulin-like growth factor 1 (IGF-1) in the liver and peripheral tissues. By directly influencing GH release, GHRH contributes to numerous physiological processes, including anabolic metabolism, protein synthesis, and cell proliferation. In addition to its classical endocrine actions, research has revealed that GHRH and its receptors are expressed in various peripheral tissues, suggesting extra-pituitary roles such as involvement in tissue repair, anti-inflammatory responses, and modulation of cellular proliferation in several systems, including the cardiovascular and immune systems.
GHRH agonists are synthetic analogs or modified versions of the native GHRH peptide that have enhanced pharmacokinetic and pharmacodynamic profiles. Most of these agonists are engineered to have improved resistance to proteolytic degradation, increased receptor-binding affinity, and prolonged half‐life compared to the endogenous peptide. Upon binding to the GHRH-R, these agonists stimulate the cyclic adenosine monophosphate (cAMP) pathway through activation of adenylate cyclase. This, in turn, promotes GH secretion from the pituitary. Beyond their effects on GH, GHRH agonists have been shown to exert direct cellular actions on various tissues such as promoting cell proliferation and tissue repair, modulating inflammatory pathways, and even offering cytoprotective benefits in settings such as ischemic injury or diabetic conditions. In essence, the agonists not only trigger the conventional GHRH–GH–IGF-1 axis but also activate downstream pathways (e.g., the PI3K/AKT and ERK/MAPK pathways) that are critical for mediating a diverse set of biological functions.
Based on the structured references extracted from the Synapse database, several GHRH agonists currently under clinical investigation are prominent in a range of studies targeting diverse clinical conditions. Notably, many of these agents are variants or formulations of the well-known GHRH analog tesamorelin, alongside other investigational compounds that belong to the growth hormone–releasing factor analog family. The following summarizes the key agents and their trial designations:
Collectively, these clinical trials represent a robust portfolio of studies utilizing GHRH agonists—primarily tesamorelin (commercially known as EGRIFTA®) and the investigational agent TH9507—in various patient populations, especially among HIV-positive individuals as well as patients with metabolic, cognitive, and cardiovascular concerns.
A closer inspection of the clinical trial phases reveals that the portfolio is diverse in terms of development stage, ranging from early-phase pharmacokinetic studies to advanced Phase II and long-term observational trials:
The clinical trials listed above demonstrate that GHRH agonists are now being evaluated for a wider array of therapeutic indications beyond traditional growth hormone deficiency. From the current trials, several key therapeutic targets can be distinguished:
The rationale behind using GHRH agonists in these therapeutic areas rests on several expected benefits:
